5 results about "Hypoxic ischemic" patented technology

Electrophysiologic biomarkers for prognostication of neurological outcome are described herein. An inverse correlation was found between timing of a cortical spreading depolarization (SD) wave and neurological outcome as tested at 24 hours post-CPR. Additionally, a minor image of this SD was identified as a “repolarization (RP) wave.” Quantifying features of SD and RP during cardiac arrest and cardiopulmonary resuscitation (CPR) provide important metrics for diagnosis and prognosis of neurological injury from hypoxia-ischemia and can serve as an early prognostication tool for predicting outcome at subsequent days after successful CPR. This discovery may also allow for novel therapeutic interventions to improve neurological recovery after hypoxia-ischemia insults.

The present invention provides the use of compound P57 or its analogs for hypothermia and neuroprotection. Specifically, the present invention provides the use of a compound represented by Formula I below for the preparation of a pharmaceutical composition for lowering the body temperature of a subject. The compound can be used for neuroprotection against hypoxic-ischemic diseases. #imgabs0#

The invention discloses an application of NORAD in regulation and control of a hypoxic ischemic neuron death mode, and relates to the technical field of biomedicine. Experiments prove that the neuron overexpresses NORAD, so that the cell viability after hypoxia and ischemia is increased, and the mitochondrial DNA copy number is increased, that is, the neuron mitochondrial activity and metabolism can be improved through NORAD overexpression, the neuron cell viability after hypoxia and ischemia is increased, and the method can reduce neuron apoptosis and necrotic apoptosis increase after hypoxia and ischemia.

The application discloses a kind of functionalization exosome-traditional Chinese medicine small molecule composite preparation T-pEXOs@GB and its preparation method and application.The composite preparation encapsulates ginkgolide B (GB) in the exosome of healthy plasma, and is functionally modified neuron target peptide RVG (DSPE-PEG-RVG) on its surface, so that it has brain targeting and oxygen supply functions.The preparation method provided by the application can efficiently and controllably prepare the composite preparation with uniform particle size and good stability.The T-pEXOs@GB composite preparation of the application can be targeted to deliver to brain ischemia and hypoxia injury area, significantly reduce oxidative stress and inflammatory response, reduce cerebral infarction volume, improve neurological deficit score, and improve the survival rate of animal model, and can be used to prepare drugs for preventing and treating acute high altitude cerebral hypoxia, ischemic stroke, neonatal hypoxic-ischemic encephalopathy and other cerebral ischemia and hypoxia injury, and has good market prospect.